Senaste uppdateringen :
19/11/2024
Immunsuppressivum   Mycophenolate mofetil  
injektion
Oral lösning
Lösningars stabilitet Stabilitet i blandningar Faktorer som påverkar stabiliteten Kompatibilitet Administreringssätt Hänvisningar pdf
   Molekylstruktur  

Varunamn   Varunamn     

Angivna handelsnamn på läkemedel är enbart vägledande då formulering inklusive hjälpämnen kan variera mellan länder och tillverkare

Cellcept Australien, Colombia, Danmark, Finland, Förenta Staterna, Frankrike, Grekland, Irland, Italien, Japan, Kanada, Luxemburg, Mexiko, Nederländerna, Norge, nya Zeeland, Österrike, Polen, Portugal, Schweiz, Spanien, Storbritannien, Sverige, Tyskland, Ungern
Micofenolato de mofetilo Spanien
Mycophenolate mofetil Belgien, Storbritannien, Tyskland
Hänvisningar   injektion   Hänvisningar : Mycophenolate mofetil  
Typ Publikation
1981 tidningen Certain E, Beteta F, Goudou-Sinha C, Darbord JC, Prognon P, Jacquot C.
Stability of i.v. mycophenolate mofetil in 5% dextrose injection in polyvinyl chloride infusion bags.
Am J Health-Syst Pharm 2002 ; 59: 2434-2439.
1982 tidningen Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2108 tidningen Trusley C, Kupiec TC, Trissel LA.
Compatibility of micafungin injection with other drugs during simulated Y-site co-administration.
Int J Pharm Compound 2006 ; 10: 230-232.
2192 tidningen Cochran BG, Sowinski KM, Fausel C, Overholser BR.
Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs.
Am J Health-Syst Pharm 2007 ; 64, 13: 1410-1414.
2247 tidningen Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
3728 tidningen Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B.
Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3828 affisch Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 affisch So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
4055 tidningen Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4299 tidningen Ezquer-Garin C, Ferriols-Lisart R, Alos-Alminana M.
Stability of mycophenolate mofetil in polypropylene 5% dextrose infusion bags and chemical compatibility associated with the use of the EQUASHIELD® closed-system transfer device.
Biomed Chromatogr 2019 ; 33, 7: e4529.
4528 tidningen Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4698 tidningen Ayari G, D'Huart E, Vigneron J, Demoré B.
Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs.
Pharmaceutical Technology in Hospital Pharmacy 2022

  Mentions Légales